Veracyte, Inc. (NASDAQ:VCYT) Q4 2023 Earnings Conference Call February 22, 2024 4:30 PM ET
Company Participants
Shayla Gorman - Senior Director of Investor Relations
Marc Stapley - Chief Executive Officer
Rebecca Chambers - Chief Financial Officer
Conference Call Participants
Sung Ji Nam - Scotiabank
Dustin Scaringe - William Blair
Matt Sykes - Goldman Sachs
Puneet Souda - Leerink Partners
Operator
Good day, and thank you for standing by. Welcome to the Veracyte Fourth Quarter and Full Year 2023 Financial Results Webcast. At this time, all participants are in a listen-only mode. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to pass the call over to the Senior Director of Investor Relations, Shayla Gorman. Please go ahead.
Shayla Gorman
Good afternoon, everyone, and thanks for joining us today for a discussion of our fourth quarter and full year 2023 financial results. With me today are Marc Stapley, Veracyte's Chief Executive Officer; and Rebecca Chambers, our Chief Financial Officer.
Veracyte issued a press release earlier this afternoon detailing our fourth quarter and full year 2023 financial results. This release, along with the business and financial presentation is available in the Investor Relations section of our website at veracyte.com.
Before we begin, I'd like to remind you that various statements that we may make during this call will include forward-looking statements as defined under applicable securities laws. Forward-looking statements are subject to risks and uncertainties, and the company can give no assurance they will prove to be correct.
Further, we are not under any obligation to provide further updates on our business trends or our performance during the quarter. To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the documents that Veracyte files with the Securities and Exchange Commission, including Veracyte's most recent forms 10-Q and 10-K.
In addition, this call will include certain non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures are included in today's earnings release accessible from the IR section of Veracyte's website.
I will now turn the call over to Marc Stapley, Veracyte's CEO.
Marc Stapley
Thanks, Shayla, and thanks everyone for joining us today. I'm pleased to share that 2023 was a record year for Veracyte. Our high value tests improved care for more than 125,000 patients and their physicians, enabling better diagnosis, prognosis and treatment decisions.